{"id":"alpha-blocker-alfuzosin","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Dizziness"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This is achieved by blocking alpha-1 adrenergic receptors, which are responsible for the contraction of smooth muscle in the prostate and bladder neck. By blocking these receptors, alfuzosin reduces the muscle tone in these areas, allowing for smoother urine flow.","oneSentence":"Alpha blockers, such as alfuzosin, work by relaxing the muscles in the prostate and bladder neck, making it easier to urinate.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:08:24.805Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Benign prostatic hyperplasia (BPH)"}]},"trialDetails":[{"nctId":"NCT07018934","phase":"","title":"Alfuzosin and Mirabegron for Double-J Stent Symptoms","status":"COMPLETED","sponsor":"University of Gaziantep","startDate":"2024-06-01","conditions":"Ureteral Stent-Related Symptoms","enrollment":100},{"nctId":"NCT00836823","phase":"PHASE4","title":"Evaluation of Symptom-specific Goal Achievement","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2005-12","conditions":"Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms","enrollment":130},{"nctId":"NCT05094947","phase":"NA","title":"Intermittent Catheterization Versus Trial Without Catheter","status":"UNKNOWN","sponsor":"Moscow State University of Medicine and Dentistry","startDate":"2021-08-03","conditions":"Benign Prostatic Hyperplasia","enrollment":200},{"nctId":"NCT00103402","phase":"PHASE3","title":"Trial to Compare Alfuzosin Versus Placebo in the Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2005-02","conditions":"Prostatitis","enrollment":272},{"nctId":"NCT01323998","phase":"","title":"Benign Prostatic Hypertrophy Treatment Patterns & Outcomes: Marketscan","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-04","conditions":"Prostatic Hyperplasia","enrollment":35032},{"nctId":"NCT01332435","phase":"","title":"Dutasteride in Enlarged Prostate Economic Assessment: A Retrospective Database Pooled Analysis of Early 5-alpha Reductase Inhibitor Use","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-11","conditions":"Prostatic Hyperplasia","enrollment":6896},{"nctId":"NCT01332487","phase":"","title":"Evaluating the Impact of Early Versus Delayed 5 Alpha Reductase Inhibitor Treatment on the Risk of Emergent Surgery in Men With Benign Prostatic Hyperplasia","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-08","conditions":"Prostatic Hyperplasia","enrollment":4068},{"nctId":"NCT01386983","phase":"","title":"Clinical and Economic Outcomes of Patients Utilizing Combination Therapy for Enlarged Prostates: A Henry Ford Database Assessment","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-03","conditions":"Prostatic Hyperplasia","enrollment":332},{"nctId":"NCT01390870","phase":"","title":"Establishing Predictors of Enlarged Prostate Treatment Adherence: Linking Symptom Improvement to Adherence","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-05","conditions":"Prostatic Hyperplasia","enrollment":400},{"nctId":"NCT01435954","phase":"","title":"Clinical Progression and Costs in Benign Prostatic Hyperplasia Patients Treated With Early Versus Delayed Combination Therapy","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-08","conditions":"Benign Prostatic Hyperplasia","enrollment":13551},{"nctId":"NCT00388271","phase":"PHASE3","title":"Use of Alfuzosin in Stone Treatment With ESWL","status":"WITHDRAWN","sponsor":"Singapore General Hospital","startDate":"2006-10","conditions":"Urinary Calculi","enrollment":""},{"nctId":"NCT00576823","phase":"PHASE3","title":"Alfuzosin Treatment in Children and Adolescents With Hydronephrosis of Neuropathic Etiology","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-12","conditions":"Hydronephrosis, Neurogenic Bladder","enrollment":25},{"nctId":"NCT00549939","phase":"PHASE3","title":"Alfuzosin Treatment in Children and Adolescents With Neurogenic Urinary Bladder Dysfunction","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-10","conditions":"Neurogenic Urinary Bladder","enrollment":172},{"nctId":"NCT00679315","phase":"PHASE2","title":"Efficacy and Safety of Alfuzosin for the Treatment of Voiding Dysfunction in Female","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2008-06","conditions":"Voiding Dysfunction","enrollment":190},{"nctId":"NCT00687388","phase":"PHASE4","title":"The Clinical Efficacy of Non-steroidal Anti-inflammation Drugs in Patients With Benign Prostatic Hyperplasia","status":"WITHDRAWN","sponsor":"Samsung Medical Center","startDate":"2008-05","conditions":"Benign Prostatic Hyperplasia","enrollment":""},{"nctId":"NCT00451061","phase":"PHASE4","title":"The Efficacy of Alpha-blockers for Expulsion of Distal Ureteral Stones","status":"UNKNOWN","sponsor":"Soroka University Medical Center","startDate":"2007-04","conditions":"Renal Colic","enrollment":120},{"nctId":"NCT00399464","phase":"PHASE3","title":"Efficacy and Safety of SL77.0499-10 (Alfuzosin) Versus Placebo and Tamsulosin in Japanese Patients With Benign Prostatic Hyperplasia","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-11","conditions":"Prostatic Hyperplasia","enrollment":1177},{"nctId":"NCT00409227","phase":"PHASE2","title":"Does Treatment With Alfuzosin Increase Success Rates of (SWL) Shock Wave Lithotripsy","status":"UNKNOWN","sponsor":"Assaf-Harofeh Medical Center","startDate":"2006-12","conditions":"Urolithiasis, Nephrolithiasis, Ureterolithiasis","enrollment":150},{"nctId":"NCT00201630","phase":"PHASE3","title":"Prophylactic Vs. Therapeutic Use of Uroxatrol in Men Undergoing Brachytherapy","status":"UNKNOWN","sponsor":"New York Prostate Institute","startDate":"2005-09","conditions":"Prostate Cancer","enrollment":150}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Alpha blocker-alfuzosin","genericName":"Alpha blocker-alfuzosin","companyName":"Assaf-Harofeh Medical Center","companyId":"assaf-harofeh-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Alpha blockers, such as alfuzosin, work by relaxing the muscles in the prostate and bladder neck, making it easier to urinate. Used for Benign prostatic hyperplasia (BPH).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}